Breathing is a fundamental part of life.
It’s easy to forget how many aspects of our lives are dependent on respiratory health – from overall health to emotional well-being to physical performance. But, factors like environmental pollution work against optimal respiratory health.
AlvioLife is a patented composition of Boswellia serrata resin standardized to 30% 3-O-acetyl-11-keto-ß-boswellic acid (AKBA) and Bengal quince fruit (Aegle marmelos) extracts. This combination of natural botanical extracts works via mechanisms that help reduce inflammation. It is a synergistic blend shown to possess stronger 5-lipoxygenase (5-LOX) inhibition activity than either extract alone. Significant evidence suggests that 5–LOX has profound influence on the onset and progression of airway inflammation. Since being introduced, it has been featured in formulations to help maintain clear airways, soothe respiratory tissues and manage environmental irritants. It works well in a broad range of consumer formulations at a fast-acting, low, 200 mg/day dose.
Improvements as fast as 3 weeks†
Improves respiratory health†
Improves lung function up to 16%†
Improves aerobic exercise capacity by 7%†
Reduces upper respiratory symptoms up to 39%†
Improves perceived well-bring by 18%†
Reduces cold complaints
Low, 200 mg day / dose
† Contact PLT for information on new study
Overall Respiratory Support. Improved Immune Function. Better Quality of Life.
AlvioLife has been the subject of two human clinical trials measuring respiratory function.
In an earlier double-blind study involving subjects with bronchial asthma, thirty-six subjects took AlvioLife (200 mg/d) or a matching placebo for 56 days. AlvioLife conferred significant improvements in the clinical parameters; the emotional function (p = .0305) and asthma symptoms scores (p = .0002) were improved even at 14 days, compared with the placebo. Further, 56 days supplementation of AlvioLife resulted in significant increase in serum IFN‐γ (p = .0014) and reduction in IL‐4 (p = .0497), compared with placebo.
In a second double-blind trial, which is currently in pre-publication, healthy subjects with self-reported sensitivity to pollution took either 200 mg/d of AlvioLife or a matching placebo for six weeks. AlvioLife was found to improve lung function (FEV1) by up to 16%; lung capacity (FVC) by up to 30%; aerobic exercise capacity by up to 7% (6-minute Walk test); to reduce upper respiratory tract symptoms (WURSS-21) by up to ~40%; improved perceived immune status (ISQ) in as early as three weeks; improved psychological well-being (PGWBI) by up to 18%; and improved the percentage of CD4+ T Helper Cells. In both studies, AlvioLife was found to be safe and well-tolerated.
Subjects taking AlvioLife had greater improvements in functional respiratory outcomes
Subjects taking AlvioLife had reductions in upper respiratory symptoms AND improvements in general well-being
Ready to realize your product’s full potential?
We work closely with our customers and our world-wide suppliers to source and scientifically back innovative ingredients for your product development needs.